Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 425

Results For "RI"

10374 News Found

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership
R&D | November 25, 2025

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership

The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating


Abbott to acquire Exact Sciences for $21 billion
News | November 25, 2025

Abbott to acquire Exact Sciences for $21 billion

Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology


Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi
Drug Approval | November 24, 2025

Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi

Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis


Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
News | November 24, 2025

Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab

AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions


FDA nod to groundbreaking bladder cancer combo therapy for surgery patients
Drug Approval | November 24, 2025

FDA nod to groundbreaking bladder cancer combo therapy for surgery patients

Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options


Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla
Drug Approval | November 24, 2025

Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla

The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia


Aptus Pharma enters into urology therapy segment
News | November 24, 2025

Aptus Pharma enters into urology therapy segment

The company will soon be launching a new portfolio of products in this segment


FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures
News | November 24, 2025

FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures

Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels


FDA investigates fatal case linked to rare blood disorder drug Adzynma
News | November 24, 2025

FDA investigates fatal case linked to rare blood disorder drug Adzynma

Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme